Naurif1 mg

Naurif 1 mg Injection is indicated for: The prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, therapy including high dose cisplatin. The prevention and treatment of postoperative nausea and vomiting.Naurif 1 mg Tablet is indicated for ... Read moreNaurif 1 mg Injection is indicated for: The prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, therapy including high dose cisplatin. The prevention and treatment of postoperative nausea and vomiting.Naurif 1 mg Tablet is indicated for: Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high dose of cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.

Anti-emetic drugs, Supportive Care Therapy

Naurif 1 mg is a highly selective 5-HT3 receptor antagonist with little or no affinity for other serotonin receptors. It blocks serotonin peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone.Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT3 receptors, Naurif 1 mg blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferret animal model, a single Naurif 1 mg injection prevented vomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds.In most human studies, Naurif 1 mg has had little effect on blood pressure, heart rate or ECG. No evidence of an effect on plasma prolactin or aldosterone concentrations has been found in other studies.

Tablet- Emetogenic Chemotherapy: The recommended adult dosage of oral Naurif 1 mg is 2 mg once daily or 1 mg twice daily. In the 2 mg once-daily regimen, two 1 mg tablets is given up to 1 hour before chemotherapy. In the 1 mg twice-daily regimen, the first 1 mg tablet is given up to 1 hour before chemotherapy, and the second tablet is given 12 hours after the first. Either regimen is administered only on the day(s) chemotherapy is given. Continued treatment, while not on chemotherapy, has not been found to be useful. Injection- Chemotherapy Induced Nausea and Vomiting: Adults: The recommended dosage for Naurif 1 mg Injection is 10 mcg/kg administered intravenously within 30 minutes before initiation of chemotherapy, and only on the day(s) chemotherapy is given. Naurif 1 mg Injection may be administered intravenously either undiluted over 30 seconds, or diluted with 0.9% Sodium Chloride or 5% Dextrose and infused over 5 minutes. As a general precaution, Naurif 1 mg Injection should not be mixed in solution with other drugs. Paediatric Patients: The recommended dose in paediatric patients 2 to 16 years o f age is 10 mcg/kg. Paediatric patients under 2 years o f age have not beenstudied. Geriatric Patients, Renal Failure Patients or Hepatically Impaired Patients: No dosage adjustment is required. Treatment of Postoperative Nausea and Vomiting: Adults: The recommended dosage for prevention of postoperative nausea and vomiting is, a single dose of 1 mg of Naurif 1 mg should be diluted to 5 ml andadministered as a slow intravenous injection (over 30 seconds). Administration should be completed prior to induction of anesthesia. The recommended dosage for the treatment of nausea and vomiting after surgery is 1 mg of Naurif 1 mg undiluted, administered intravenously over 30 seconds. Paediatric Patients: Safety and effectiveness of Naurif 1 mg Injection have not been established in paediatric patients for the prevention or treatment of post operative nausea or vomiting. Geriatricpatients, Renal Failure Patients or Hepatically Impaired Patients: No dosage adjustment is required.

Naurif 1 mg Injection:Chemotherapy-induced nausea and vomiting: Adults: The recommended dosage for Naurif 1 mg Injection is 10mcg/kg administered intravenously within 30 minutes before initiation of chemotherapy and only on the day(s) chemotherapy is given. Naurif 1 mg Injection may be administered intravenously either undiluted over 30 seconds or diluted with 0.9% Sodium Chloride or 5% Dextrose and infused over 5 minutes. As a general precaution, Naurif 1 mg Injection should not be mixed in solution with other drugs. Pediatric Patients: The recommended dose in pediatric patients 2 to 16 years of age is 10mcg/kg. Pediatric patients under 2 years of age: Have not been studied. Geriatric Patients, Renal Failure Patients or Hepatically Impaired Patients: No dosage adjustment is required. Treatment of postoperative nausea and vomiting: Adults: The recommended dosage for prevention of postoperative nausea and vomiting is, a single dose of 1 mg of Naurif 1 mg should be diluted to 5 ml and administered as a slow intravenous injection (over 30 seconds).Administration should be completed prior to induction of anesthesia. The recommended dosage for the treatment of nausea and vomiting after surgery is 1 mg of Naurif 1 mg undiluted, administered intravenously over 30 seconds. Paediatric Patients: The safety and effectiveness of Naurif 1 mg Injection have not been established in pediatric patients for the prevention or treatment of postoperative nausea or vomiting. Geriatric patients, Renal Failure Patients or Hepatically Impaired Patients: No dosage adjustment is required. Naurif 1 mg Tablet: Emetogenic chemotherapy: The recommended adult dosage of oral Naurif 1 mg is 2 mg once daily or 1 mg twice daily. In the 2 mg once-daily regimen, two 1 mg tablets are given up to one hour before chemotherapy. In the 1 mg twice-daily regimen, the first 1 mg tablet is given up to one hour before chemotherapy, and the second tablet, 12 hours after the first. Either regimen is administered only on the days(s) chemotherapy is given. Use in the Elderly, Renal Failure Patients or Hepatically Impaired Patients: No dosage adjustment is required. Radiation (either total body irradiation or fractionated abdominal radiation): The recommended adult dosage of oral Naurif 1 mg is 2 mg once daily. Two 1 mg tablets are taken within one hour of irradiation. Pediatric use: There is no experience with oral Naurif 1 mg in the prevention of radiation-induced nausea and vomiting in pediatric patients.

Naurif 1 mg does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system. As Naurif 1 mg is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and the half-life of Naurif 1 mg.

Naurif 1 mg is contraindicated in patients with known hypersensitivity to Naurif 1 mg or any of its components.

Headache, constipation, asthenia, diarrhea, abdominal pain, dyspepsia, nausea and vomiting, dizziness, insomnia, and anxiety.

Pregnancy Category B. No evidence of impaired fertility or harm to the animal fetus have been found. However, this drug may be used in pregnancy only if clearly needed. It is not known whether Naurif 1 mg is excreted in human milk. So cautions hould be exercised when Naurif 1 mg is administered to a nursing mother.

Patient with cardiac co-morbidities, on cardiotoxic chemotherapy and/or woth concomitant electrolyte abnormalities. May mask progressive ileus and/or gastric distention. Childn. Pregnancy and lactation.

lnjection: Store below 25°C.Protect from light. Tablet: Store below °C.Protect from light.

Pediatric Uses: Safety and effectiveness of Naurif 1 mg in paediatric patients under 2 years have not been established. Geriatric use: Efficacy and safety were maintained with increasing age

Anti-emetic drugs, Supportive Care Therapy

Naurif 1 mg is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.

Pregnancy category B. No evidence of impaired fertility or harm to the animal fetus has been found. However, this drug may be used in pregnancy only if clearly needed. It is not known whether Naurif 1 mg is excreted in human milk. So caution should be exercised when Naurif 1 mg is administered to a nursing mother.

Pediatric Uses: The safety and effectiveness of Naurif 1 mg in pediatric patients under 2 years have not been established.Geriatric use: Efficacy and safety were maintained with increasing age.